~~<i id='CCD01E8FE5'><strike id='CCD01E8FE5'><tt id='CCD01E8FE5'><pre id='CCD01E8FE5'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：knowledge 2025-10-01 02:20:31 Page View：88

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing
Next article： Psychedelics group wrestles with new pharma identity

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Attacks on the drug industry will lead to fewer breakthroughs

TedW.Love,sittingintheplaidshirt,withhisfamilyin1964CourtesyTedLoveIwasborninAlabamaintheJimCrowSout

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop